Eton Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 09:26 pm
Share
Eton Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 7.03 million compared to USD 3.22 million a year ago. Net loss was USD 0.579 million compared to USD 3.05 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.12 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.12 a year ago.
For the nine months, revenue was USD 24.33 million compared to USD 12.75 million a year ago. Net income was USD 1.32 million compared to net loss of USD 9.93 million a year ago. Basic earnings per share from continuing operations was USD 0.05 compared to basic loss per share from continuing operations of USD 0.4 a year ago. Diluted earnings per share from continuing operations was USD 0.05 compared to diluted loss per share from continuing operations of USD 0.4 a year ago.
Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.